Search Within

Gregory J Riely

  1. "Hira Rizvi"
Formats
  1. Journal Article (26)
  2. Meeting Abstract (16)
Groups
  1. Department of Medicine (42)
  2. Solid Tumor Oncology Division (42)
  3. Thoracic Oncology (42)
  4. GSK Faculty (34)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (32)
  6. Human Oncology and Pathogenesis Program (31)

More Groups

People
  1. Hira Rizvi (42)
  2. Matthew Hellmann (25)
  3. Marc Ladanyi (24)
  4. Mark Kris (19)
  5. Charles Rudin (18)
  6. Adam Schoenfeld (17)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (8)
  4. 2021 (10)
  5. 2020 (8)
  6. 2019 (7)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Clinical Cancer Research (7)
  3. Annals of Oncology (5)
  4. Cancer Research (4)
  5. Journal of Thoracic Oncology (4)
  6. Cancer Discovery (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (14)
  2. American Association for Cancer Research (13)
  3. Oxford University Press (6)
  4. Elsevier Inc. (4)
  5. American Medical Association (3)
  6. Biomed Central Ltd (1)

More Publishers

Results (42)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer
    Journal Article

    Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer
    Journal Article

    Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Rizvi, H.; Elkrief, A.; Luo, J.; Alessi, J. V.; Pecci, F.; Lamberti, G.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
    Journal Article

    Elkrief, A.; Alessi, J. M. V.; Ricciuti, B.; Brown, S.; Rizvi, H.; Preeshagul, I. R.; Wang, X.; Pecci, F.; Di Federico, A.; Lamberti, G.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Elkrief, A.; Bowman, A.; Rizvi, H.; Hellmann, M.; Riely, G. J.; Schoenfeld, A. J.; Ladanyi, M.; Vanderbilt, C. M.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer
    Meeting Abstract

    Elkrief, A.; Machado Alessi, J. V.; Ricciuti, B.; Rizvi, H.; Preeshagul, I. R.; Egger, J. V.; Chaft, J. E.; Rudin, C. M.; Riely, G. J.; Kris, M. G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis
    Journal Article

    Van Egeren, D.; Kohli, K.; Warner, J. L.; Bedard, P. L.; Riely, G.; Lepisto, E.; Schrag, D.; LeNoue-Newton, M.; Catalano, P.; Kehl, K. L.; more...
    Scientific Reports (2022)

    Fulltext@MSK | Save
  • Genomic landscapes and hallmarks of mutant RAS in human cancers
    Journal Article

    Scharpf, R. B.; Balan, A.; Ricciuti, B.; Fiksel, J.; Cherry, C.; Wang, C.; Lenoue-Newton, M. L.; Rizvi, H. A.; White, J. R.; Baras, A. S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer
    Journal Article

    Schoenfeld, A. J.; Rizvi, H. A.; Memon, D.; Shaverdian, N.; Bott, M. J.; Sauter, J. L.; Tsai, C. J.; Lihm, J.; Hoyos, D.; Plodkowski, A. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • AACR project GENIE: 100,000 cases and beyond
    Journal Article

    Pugh, T. J.; Bell, J. L.; Bruce, J. P.; Doherty, G. J.; Galvin, M.; Green, M. F.; Hunter-Zinck, H.; Kumari, P.; Lenoue-Newton, M. L.; Li, M. M.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save